Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study
1998

Microencapsulated Octreotide Pamoate in Advanced Cancer

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): Si Hellel, J Geisler, JP Poulsen, K Hestdal, K Meadows, W Collins, KM Tveit, A Vistes, JMP Holly, PE Lonning

Primary Institution: Haukeland University Hospital

Hypothesis

Can microencapsulated octreotide pamoate improve treatment outcomes in patients with advanced gastrointestinal and pancreatic cancer?

Conclusion

Microencapsulated octreotide is well tolerated and significantly affects several components of the IGF system in plasma.

Supporting Evidence

  • Two patients had stable disease for 4 and 6 months.
  • Plasma IGF-I decreased by 49-53% and IGF-II by 27-37%.
  • Insulin and C-peptide levels decreased by 29-38% and 41-46%, respectively.

Takeaway

This study tested a new medicine on 14 patients with serious cancer, and it seemed to help their bodies in some ways without causing bad side effects.

Methodology

Patients received different doses of microencapsulated octreotide pamoate, and their blood was tested for various hormone levels over time.

Limitations

The study had a small sample size and was limited to specific cancer types.

Participant Demographics

Median age was 64 years, with 8 men and 6 women.

Statistical Information

P-Value

p<0.05

Confidence Interval

95%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication